Search research articles
Contact Us
Filters
Showing results (41-50 of 65) with videos related to
Page
of 7
Sort By:
The Lancet. Oncology
|
April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Charlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
British Journal of Haematology
|
July 18, 2020
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy
Thomas A Fox, Ethan Troy-Barnes, Amy A Kirkwood, et al.
Hemasphere
|
June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
Maeve A O'Reilly, William Wilson, David Burns, et al.
Nature Medicine
|
April 6, 2023
Tumor inflammation-associated neurotoxicity
Jasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2023
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Gloria Iacoboni, Víctor Navarro, Ana África Martín-López, et al.
Cancer Research Communications
|
June 4, 2026
CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
Claire Roddie, William Day, Meera Raymond, et al.
Molecular Therapy. Advances
|
May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL
Claire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
Hemasphere
|
July 1, 2024
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
Gloria Iacoboni, Mario A Sánchez-Salinas, Kai Rejeski, et al.
British Journal of Haematology
|
March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
Maeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Blood
|
July 11, 2025
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Claire Roddie, Juliana Dias, Maeve O'Reilly, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 65) with videos related to
Sort By:
Page
of 7
The Lancet. Oncology
|
April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Charlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
British Journal of Haematology
|
July 18, 2020
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy
Thomas A Fox, Ethan Troy-Barnes, Amy A Kirkwood, et al.
Hemasphere
|
June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
Maeve A O'Reilly, William Wilson, David Burns, et al.
Nature Medicine
|
April 6, 2023
Tumor inflammation-associated neurotoxicity
Jasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2023
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Gloria Iacoboni, Víctor Navarro, Ana África Martín-López, et al.
Cancer Research Communications
|
June 4, 2026
CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
Claire Roddie, William Day, Meera Raymond, et al.
Molecular Therapy. Advances
|
May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL
Claire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
Hemasphere
|
July 1, 2024
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
Gloria Iacoboni, Mario A Sánchez-Salinas, Kai Rejeski, et al.
British Journal of Haematology
|
March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
Maeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Blood
|
July 11, 2025
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Claire Roddie, Juliana Dias, Maeve O'Reilly, et al.
Page
of 7